Genentech

Milestones as listed on gene.com, checked 26 Sep 2026. Details can change; the linked page is the authoritative source.

Leadership as listed on gene.com, checked 26 Sep 2026. Details can change; the linked page is the authoritative source.

Products and services as listed on gene.com, checked 26 Sep 2026. Details can change; the linked page is the authoritative source.

What public registers list for Genentech: clinical trials it sponsors, FDA device clearances, Irish licences, recent approvals and supply shortages. Rebuilt daily, last on 6 Oct 2026.

Clinical trials 39 in our ClinicalTrials.gov registers · 2 in the EU register

Showing 10 of 39, trials with Irish sites first. The full lists are on the sponsor pages below.

All trials by sponsor name 1 registry name

Drugs in these trials 48 compounds

EU trials register (CTIS) 2 authorised or ongoing

• A Phase Ib/ II Multicenter, Open-Label, Randomized Study Evaluating the Safety, Pharmacokinetics, and Activity of GDC-4198 Alone and in Combination with Giredestrant in Comparison with Abemaciclib and Giredestrant in Participants with Locally Advanced or Metastatic Estrogen Receptor-Positive, HER2-Negative Breast Cancer who Have Previously Progressed During or After a CDK4/6 Inhibitor2025-521128-31-00 · Phase I/II · Ongoing
• Clinical Study to Evaluate the Effects of Cevostamab in Patients with Lupus with or without Active Lupus Nephritis2025-522904-26-00 · Phase I · Ongoing

Medicine shortages 1 in the FDA list

• Alteplase InjectionUS (FDA) · resolved · updated 21 May 2026

A company is listed here when it is named on the shortage record; a shortage can have several manufacturers. See the US and German shortage trackers.

NICE technology appraisals 47 of its medicines · 47 current

• Nusinersen and risdiplam for treating spinal muscular atrophyNICE TA1162 · Recommended, Optimised · 4 Jun 2026
• Entrectinib for treating NTRK fusion-positive solid tumours in people 12 years and over (terminated appraisal)NICE TA1118 · Terminated (no company submission) · 7 Jan 2026
• Glofitamab with gemcitabine and oxaliplatin for treating relapsed or refractory diffuse large B-cell lymphomaNICE TA1113 · Optimised · 3 Dec 2025
• Atezolizumab for adjuvant treatment of resected non-small-cell lung cancerNICE TA1071 · Recommended · 19 Jun 2025
• Atezolizumab for untreated advanced or recurrent non-small-cell lung cancer when platinum-doublet chemotherapy is unsuitable (terminated appraisal)NICE TA1047 · Terminated (no company submission) · 12 Mar 2025
• Crovalimab for treating paroxysmal nocturnal haemoglobinuria in people 12 years and overNICE TA1019 · Recommended · 20 Nov 2024
• Faricimab for treating visual impairment caused by macular oedema after retinal vein occlusionNICE TA1004 · Recommended · 11 Sep 2024
• Satralizumab for preventing relapses in neuromyelitis optica spectrum disorders (terminated appraisal)NICE TA960 · Terminated (no company submission) · 27 Mar 2024

Appraisals of medicines sold under a brand this company holds in EMA or FDA records, from our NICE appraisals register. NICE decisions apply to the NHS in England. © NICE 2026 technology appraisal guidance. Available from www.nice.org.uk/guidance. All rights reserved. Subject to Notice of rights. NICE guidance is prepared for the National Health Service in England. All NICE guidance is subject to regular review and may be updated or withdrawn. NICE accepts no responsibility for the use of its content in this product/publication.

Group (Genentech): founded 1966, headquarters Basel, website roche.com. Wikidata Q25463170 · Wikipedia. From Wikidata (CC0), matched by the group's Legal Entity Identifier.

How this is matched: register records are linked to this page by the organisation name they carry, here Genentech, Inc.; Genentech Inc.; Genentech, Inc; GENENTECH; GENENTECH INC. Spot a wrong match? Tell us.

Roche Holding AG does not file annual reports with the US SEC, so we do not show its financial statements here.

Companies registered in Ireland 3 active in the CRO register

From the Companies Registration Office (CRO Open Data, CC BY 4.0). A company is listed when GLEIF's legal entity register links it to Roche Holding AG as its ultimate parent, or when we checked its name and registered address by hand. Branches of foreign companies appear as "External company". Spot a missing or wrong entry? Tell us.